| CRNX - Crinetics Pharmaceuticals Inc (Healthcare: Biotechnology) | Projected Earnings Date: 2025-08-07 (Delayed quote data 2025-05-09) |
|
|
|||||||||||||||||
|
|
|
| Company Profile | |
| Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidates include paltusotine which is in clinical development for the treatment of acromegaly and neuroendocrine tumors, or NETs, CRN04777, which is in clinical development for congenital hyperinsulinism, or HI, and CRN04894, which is in clinical development for diseases of excess adrenocorticotrophic hormone, or ACTH, including Cushing's Disease, congenital adrenal hyperplasia, or CAH, and Ectopic ACTH Syndrome, or EAS. | |
| Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. |